Finance

Lists
VTRS:NASDAQ
Viatris Inc
USD 18,48
+0,16%
(+0,030) 1D
USD 18,48
0,00% (0,00)
After hours
Closed: 22 Okt., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VTRS...
Open
USD 18,45
High
USD 18,66
Low
USD 18,34
Mkt. cap
21,23 mjd
Avg. vol.
9,50 m
Volume
5,44 m
Dividend
2,60%
Quarterly dividend
USD 0,12
Ex-dividend date
21 Aug. 2026
52-wk high
USD 18,75
52-wk low
USD 9,92
EPS
-USD 0,36
Beta
0,86
Shares outstanding
1,15 mjd
No. of employees
30 k
Open
USD 18,45
High
USD 18,66
Low
USD 18,34
Mkt. cap
21,23 mjd
Avg. vol.
9,50 m
Volume
5,44 m
Dividend
2,60%
Quarterly dividend
USD 0,12
Ex-dividend date
21 Aug. 2026
52-wk high
USD 18,75
52-wk low
USD 9,92
EPS
-USD 0,36
Beta
0,86
Shares outstanding
1,15 mjd
No. of employees
30 k
News stories
From web sources and news partners
Pennsylvania Business Report -
Pennsylvania Business Report -
·
2 dae gelede
Viatris drug receives FDA approval
Profile
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020. The name of the corporation comes from the Latin words via, meaning path, and tris, which means three, referring to the path to three main objectives the corporation set: expanding access to medicines, meeting patient needs through innovation, and earning the trust of the healthcare community. Viatris ranked 254th on the 2021 Fortune 500 rankings of the largest United States corporations based on its 2020 total revenue. In 2026, Viatris ranked 100 on Time Magazine's World's Most Impactful Companies. Wikipedia
About Viatris Inc
CEOScott A. Smith
Employees30 k
Founded16 Nov. 2020
HeadquartersCanonsburg, Pennsilvanië, Verenigde State van Amerika
SectorPharmaceutical industry
Analyst ratings
Based on 9 analysts giving stock ratings to VTRS in the past 3 months
Buy
Buy
5
Hold
3
Sell
1
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for VTRS in the last 3 months.
Highest
Current USD 18,48
USD 26,00 (+40,69%)
Average
USD 20,22 (+9,42%)
Lowest
USD 13,00 (-29,65%)
Analyst
Recommendation
Action
Price target
Projected
Date
Chris Schott
J.P. Morgan
Hold
Reiterated
USD 20,00
+8,2%
10/21/2026
Glen Santangelo
Barclays
Buy
Maintained
USD 22,00
+19%
10/15/2026
Jason Gerberry
Bank of America Securities
Sell
Maintained
USD 16,00
-13,4%
10/12/2026
David Amsellem
Piper Sandler
Hold
Reiterated
USD 13,00
-29,7%
10/12/2026
Salveen Richter
Goldman Sachs
Hold
Maintained
USD 20,00
+8,2%
10/08/2026
Ashwani Verma
UBS
Buy
Maintained
USD 26,00
+40,7%
10/05/2026
Les Sulewski
Oppenheimer
Buy
Initiated
USD 25,00
+35,3%
09/23/2026
Unknown Analyst
Oppenheimer
Buy
Initiated
USD 25,00
+35,3%
09/23/2026
Daniel Clark
Leerink Partners
Buy
Initiated
USD 20,00
+8,2%
09/09/2026
Jasper Hellweg
Argus Research
Buy
Maintained
USD 20,00
+8,2%
09/08/2026
Unknown Analyst
Jefferies
Buy
Maintained
USD 17,00
-8%
03/20/2026
Next call oor 14 dae
Do. 5 Nov., 15:30
Fiscal period
Q3 2026
- / USD 0,64
Revenue / Est. (USD)
- / 3,79 mjd
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
3,76 mjd
3,70 mjd
3,52 mjd
3,76 mjd
Cost of goods sold
2,26 mjd
2,21 mjd
2,14 mjd
2,19 mjd
Cost of revenue
2,26 mjd
2,21 mjd
2,14 mjd
2,19 mjd
Research and development expenses
244,80 m
271,20 m
245,80 m
245,20 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
848,50 m
933,40 m
893,40 m
855,00 m
Operating expense
1,09 mjd
1,20 mjd
1,14 mjd
1,10 mjd
Total operating expenses
3,36 mjd
3,42 mjd
3,28 mjd
3,29 mjd
Operating income
404,60 m
288,20 m
238,60 m
471,50 m
Other non operating income
-135,90 m
44,90 m
-1,80 m
14,40 m
EBT including unusual items
-7,90 m
-343,00 m
-247,30 m
-64,00 m
EBT excluding unusual items
318,70 m
188,00 m
146,20 m
365,40 m
Income tax expense
120,30 m
-2,90 m
-423,70 m
54,80 m
Effective tax rate
-1 522,78%
0,85%
171,33%
-85,62%
Other operating expenses
-
-
-
-
Net income
-128,20 m
-340,10 m
176,40 m
-118,80 m
Net profit margin
-3,41%
-9,18%
5,02%
-3,16%
Earnings per share
0,67
0,57
0,59
0,69
Interest and investment income
-
-
-
-
Interest expense
-119,60 m
-119,60 m
-120,10 m
-120,70 m
Net interest expenses
-119,60 m
-119,60 m
-120,10 m
-120,70 m
Depreciation and amortization charges
-
-
-
-
EBITDA
1,09 mjd
981,10 m
914,70 m
1,14 mjd
Gain or loss from assets sale
-1,60 m
21,90 m
13,90 m
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google-programme